8-K 1 tm214030d1_8kseq1.htm FORM 8-K





Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): January 23, 2021


Osmotica Pharmaceuticals plc

(Exact name of registrant as specified in its charter)


Ireland   001-38709   Not Applicable
(State or other jurisdiction of

  (Commission File Number)   (IRS Employer

Identification No.)


400 Crossing Boulevard
Bridgewater, NJ
(Address of principal executive offices)   (Zip Code)  


(Registrant’s telephone number, including area code): (908) 809-1300


Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Ordinary Shares OSMT Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x





Item 8.01 Other Events.


On January 23, 2021, Osmotica Pharmaceuticals plc (the “Company”) submitted a Type A meeting request to the U.S. Food and Drug Administration (“FDA”) to discuss the FDA’s Complete Response Letter in connection with the Company’s New Drug Application (the “NDA”) for arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis and the CRL’s recommendations and obtain advice on a path forward for the NDA.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  By: /s/ Brian Markison
    Brian Markison
    Chief Executive Officer  


Date: January 25, 2021